Close Menu

NEW YORK – Taiwanese cancer diagnostic firm ACT Genomics said on Monday that it has launched a study in collaboration with the University of California, San Diego Moores Cancer Center that will evaluate gene expression signals associated with the tumor microenvironment that may predict outcome in melanoma patients treated with PD-1 inhibition.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.